Key facts
- Highlightll Pharma’s last known valuation is $346.2M (Nov 2025).
- It has raised $97.3M; the latest was IPO in Dec 2025.
- Notable investors include CICC Capital, Hillhouse Investment Group, Shenzhen Yifeng Investment Management Enterprise, Infinity Group, Hankang Capital — 11 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Highlightll Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Highlightll Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Highlightll Pharma
Developer of a drug development approach designed to create therapies for autoimmune and inflammatory diseases affecting systemic and central nervous system conditions. The company offers a pipeline focused on neuroinflammation and immune modulation, enabling patients with autoimmune and neurodegenerative conditions such as Alzheimer's and Parkinson's disease to access treatments intended to slow disease progression and improve quality of life.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2017
- Employees
- 100
- Website
- highlightpharma.com/
- Ownership
- In IPO Registration
Highlightll Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Highlightll Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Highlightll Pharma in its N-PORT filings yet. We sweep new filings monthly.